Prior hematologic conditions carry a high morbidity and mortality in patients supported with continuous-flow left ventricular assist devices
| Autor: | David L. Diuguid, Kanika M. Mody, Arthur R. Garan, Hiroo Takayama, Nir Uriel, Melana Yuzefpolsakaya, Yoshifumi Naka, A.P. Levin, Justin Fried, Ulrich P. Jorde |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Pediatrics medicine.medical_specialty Columbia university Postoperative Hemorrhage Actuarial survival Cohort Studies Postoperative Complications medicine Factor V Leiden Humans In patient Retrospective Studies Transplantation Continuous flow business.industry Thrombosis Middle Aged medicine.disease Hematologic Diseases Thrombocytopenic purpura Surgery Increased risk Preoperative Period Female Heart-Assist Devices Cardiology and Cardiovascular Medicine business |
| Zdroj: | The Journal of Heart and Lung Transplantation. 33:1119-1125 |
| ISSN: | 1053-2498 |
| DOI: | 10.1016/j.healun.2014.07.002 |
| Popis: | Background Mechanical support leads to an increased risk of both bleeding and thrombotic events, but little is known about the risk of device support in patients with a baseline predisposition to these events. The aim of this study was to examine outcomes among patients with baseline hematologic conditions who underwent continuous-flow LVAD implantation (CF-LVAD). Methods We retrospectively reviewed records of 286 patients who underwent CF-LVAD implantation at the Columbia University Medical Center between April 2008 and December 2013. Patients diagnosed with the following hematologic conditions were enrolled: idiopathic thrombocytopenic purpura (ITP); Factor V Leiden; elevated Factor VIII; heparin-induced thrombocytopenia (HIT); or undefined hypercoagulable state. Results Of the 286 CF-LVAD patients implanted during the study period, 12 were considered to have a significant hematologic condition predisposing them to either bleeding or thrombotic events. The study included 5 patients with ITP, 1 with Factor V Leiden, 1 with elevated Factor VIII, 2 with HIT and 3 patients with undefined hypercoagulable state. Patients were supported for a total of 168.46 months, with a median of 10.76 months (IQR 4.78 to 21.36 months). There was a high frequency of thrombotic (0.57 event per patient-year), neurologic (0.36 event per patient-year) and bleeding (0.64 event per patient-year). Actuarial survival rates at 6 and 12 months were 81.8%, but fell to 49% at 2 years. Conclusions Patients with a history of prior hematologic conditions are at high risk for bleeding, thrombotic and neurologic events during device support, leading to early mortality. This case series questions the benefit of CF-LVAD in these patients and the appropriate management with regard to anti-coagulation. Further studies on the outcomes of these patients are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|